The global Mesalamine Market demonstrated significant strength in 2021 and is projected to experience rapid revenue growth throughout the forecast period. The primary driving factor for the market's revenue growth is the increasing use of mesalamine in the treatment of ulcerative colitis. Mesalamine is a medication used to address the swelling and sores in the lining of the colon and rectum caused by this condition. It belongs to a class of medications known as anti-inflammatory agents and is the active component of sulfasalazine. When metabolized, it is converted into sulfapyridine and mesalazine. Mesalamine is considered safe and well-tolerated by patients, with minimal side effects. It is particularly effective in treating colonic diseases that involve inflammation in the large intestine and rectum, providing relief from symptoms such as inflammation, diarrhea, rectal bleeding, and stomach discomfort.
The demand for mesalamine as a treatment for ulcerative colitis is a key driver of revenue growth in the global market. Inflammatory bowel diseases, including ulcerative colitis, cause inflammation, ulcers, and sores in the large intestine and rectum, leading to significant pain and discomfort. Mesalamine helps alleviate pain, reduce inflammation, and provide relief from associated symptoms.
Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/5820
It is also used to treat other conditions such as headaches, sprains, strains, and long-term pain conditions resulting from inflammatory bowel diseases. The increasing prevalence of inflammatory colitis and its agonizing symptoms further contribute to the demand for mesalamine in hospitals, driving market revenue growth.
Key players in the Mesalamine Market:
- PharmaZell GmbH (Germany)
- Syntese A/S (Denmark)
- Cambrex Corporation (U.S.)
- Divi's Laboratories Limited (India)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Chemi S.p.A. (Italy)
- Ipca Laboratories Limited (India)
- Zydus Lifesciences Limited (India)
- Mylan N.V. (U.S.)
- Ferring B.V. (Switzerland)
These companies employ various strategies and objectives to drive growth. For example, PharmaZell GmbH completed a merger with Novasep to enhance their position as a technologically advanced, market-leading CDMO and API company. Teva Pharmaceutical Industries Ltd. launched a generic version of mesalamine suppository medicine, providing an essential therapy option for ulcerative colitis patients in the U.S.
However, the market's revenue growth may face constraints due to adverse side effects associated with mesalamine usage. Some patients may experience symptoms such as diarrhea, headache, nausea, vomiting, lower back or side pain, decreased urine frequency, bloody urine, increased thirst, loss of appetite, fatigue, face swelling, weight gain, or troubled breathing. Serious kidney problems, including the formation of kidney stones, are also correlated with mesalamine usage, reducing its demand and restraining market revenue growth.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/5820
Opportunities for market players lie in research and development projects focused on improving the efficiency of mesalamine. Currently, the drug exhibits a lag time in transporting into the large intestine after administration, delaying its effectiveness. The development of a press-coated enteric coating tablet format could reduce this lag time and enhance the drug's residence length in the colon, leading to quicker and longer-lasting anti-inflammatory activity. pH-time dependent delivery systems have also shown promising results in keeping the medicine in the upper gastrointestinal tract while activating it in the colon. These advancements present opportunities for market growth.
Regarding the global mesalamine market revenue growth driven by product segments, the purity ≥ 98% segment is expected to experience significant growth. This is due to its better anti-inflammatory, antioxidative, and anticancer properties compared to other purities. The solubility and absorption of this type can be increased by putting it in an ultrasonic bath, making it convenient for usage. The prepared solution can be stored at temperatures below -20°C for an extended period, enhancing its applicability. Additionally, its versatility in preparation and suppression of colon cancer cell proliferation contribute to its increasing demand and revenue growth.
In terms of application, the tablets segment is expected to register significant revenue growth. Tablets are well tolerated, providing effective results within 2 to 4 weeks of proper usage. They are not associated with an increased risk of infection or malignancy, making them preferred for usage. Tablets are available in different concentrations and can be easily administered orally, making them practical for repeated and extended use in the treatment of inflammatory bowel diseases. Their cost-effectiveness and low risk of acute medication response further increase demand and drive revenue growth.
Regionally, Europe is anticipated to account for the largest revenue share in the global mesalamine market. The region has observed increased rates of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Factors such as immune system dysfunction and heredity contribute to the rising cases, leading to increased research and development efforts and driving revenue growth. In North America, the market is expected to experience a steady revenue compound annual growth rate due to the highest age-standardized prevalence rates for inflammatory bowel disease. Ulcerative colitis, in particular, is more common in this region, further contributing to the demand for mesalamine and driving revenue growth.
In summary, the global mesalamine market is expected to experience rapid revenue growth driven by the increasing use of mesalamine in the treatment of ulcerative colitis. The market presents opportunities for research and development projects to enhance the drug's efficiency. The purity ≥ 98% segment and tablets segment are expected to contribute significantly to revenue growth. Europe and North America are the key regions driving market growth. Major companies employ strategies such as mergers, acquisitions, and product launches to strengthen their market presence.
Request a customized copy of the report @
https://www.reportsanddata.com/request-customization-form/5820
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports:
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact:
John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
LinkedIn | Twitter | Blogs
English
العربية
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Română
Português
Ελληνικά